Potential for amino acids supplementation during inflammatory bowel diseases

• Published in: Inflammatory bowel diseases Vol. 16; no. 3; pp. 518 - 524
• Main Authors: Coeffier, Moise, Marion-Letellier, Rachel, Dechelotte, Pierre
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2010
• Subjects: Amino Acids - therapeutic use; arginine; Colitis, Ulcerative - diet therapy; Colitis, Ulcerative - physiopathology; Crohn Disease - diet therapy; Crohn Disease - physiopathology; Crohn's disease; Dietary Supplements; glutamine; Humans; Malnutrition - diet therapy; Malnutrition - physiopathology; nutrition; ulcerative colitis
• ISSN: 1078-0998; 1536-4844
• DOI: 10.1002/ibd.21017

: The pathophysiology of inflammatory bowel diseases (IBDs) is multifactorial and involves interactions of gut luminal content with mucosal barrier and especially immune cells. Malnutrition is a frequent issue during IBD flares, especially in Crohn's disease (CD) patients, and nutritional support is frequently used to treat malnutrition but also in an attempt to modulate intestinal inflammation. The use of oral or enteral nutrition intervention in IBDs may be effective, alone or in combination with drugs, to achieve and maintain remission. However, standard diets are less effective than new‐generation biotherapies and could be improved by supplementation with specific immunomodulatory amino acids. Experimental studies evaluating glutamine, the preferential substrate for enterocytes, are promising. Some clinical studies with oral glutamine in CD are until now disappointing, but new formulations and targeting could enhance glutamine efficacy at the site of mucosal lesions. The role of arginine, involved in nitric oxide and polyamines synthesis, still remains debated. However, the effects of these amino acids in IBD have been poorly documented in humans. Other candidates like glycine, cysteine, histidine, or taurine should also be evaluated in the future. (Inflamm Bowel Dis 2010)